SAM
SRPT icon

Securian Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Securian Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,484
Closed -$128K – 941
2025
Q2 		$128K Buy
7,484
+263
+4% +$11.2K ﹤0.01% 926
2025
Q1 		$461K Hold
7,221
– – 0.01% 703
2024
Q4 		$878K Sell
7,221
-189
-3% -$23.2K 0.03% 475
2024
Q3 		$925K Sell
7,410
-100
-1% -$13.8K 0.03% 468
2024
Q2 		$1.19M Buy
+7,510
New +$965K 0.03% 370

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Securian Asset Management's SRPT Position: Q3 2025 in Review

Securian Asset Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 7,484 shares — an estimated $128K sold.

Securian Asset Management first reported a position in SRPT in Q2 2024 and held it in 5 quarters. The position peaked at $1.19M in Q2 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Securian Asset Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Securian Asset Management sold 7,484 Sarepta Therapeutics shares in Q3 2025, an estimated $128K.
  • Securian Asset Management first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 5 quarters.
  • Securian Asset Management's Sarepta Therapeutics position peaked at $1.19M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Securian Asset Management's 13F filing for Q3 2025, filed 23 Oct 2025.